Evaluation of Apolipoprotein A1 and Posttranslationally Modified Forms of Transthyretin as Biomarkers for Ovarian Cancer Detection in an Independent Study Population

Moore, Lee E.; Fung, Eric T.; McGuire, Marielena; Rabkin, Charles; Molinaro, Annette M.; Wang, Zheng; Zhang, Fujun; Wang, Jing; Yip, Christine; Meng, Xiangyi; Pfeiffer, Ruth M.

doi:10.1158/1055-9965.epi-05-0980

Cited by 82 publications

(70 citation statements)

References 21 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhang et al [3] clearly demonstrated that the levels of Apolipoprotein A-I and transthyretin are both down-regulated in patients with ovarian cancer, and inter-alpha trypsin inhibitor heavy chain H4 was up-regulated. Moore et al [16] was able to replicate these findings, and interestingly, in our study, the expression of chain D retinol-binding protein with transthyretin was also shown to be down-regulated. Roberts et al [17] reported that decreased levels of retinol binding protein have been shown to be associated with an increased rate of malignant transformation of the ovarian epithelium and expression may be lost as early as stage 1 and at high frequency.…”

Section: Discussionsupporting

confidence: 86%

Proteomic Profiling of Ovarian Cancer Plasma using Immunoaffinity Depleted Plasma and Two-Dimensional PAGE

Oliva¹,

Ayhan²,

Barker³

et al. 2007

Clin Proteom

View full text Add to dashboard Cite

Objective The aim of this study was to evaluate a multiple immunoaffinity protein depletion (multiple affinity removal system, MARS) pre-treatment strategy with subsequent two-dimensional polyacrylamide gel electrophoresis (2D PAGE) and peptide mass finger printing analysis for the detection of ovarian cancer-associated plasma proteins. Materials and Methods Following immunoaffinity depletion, total plasma protein content was reduced by 84.2± 1.8% (mean±SE, n=32). The number of proteins detected in the control and ovarian cancer groups was 349 and 357, respectively. This represented an increase in spot detection of almost twofold when compared to 2D PAGE displays of untreated plasma (174 spots). Of the proteins displayed, post-depletion, 300 (control) and 302 (ovarian cancer, OC) were common within each group. PDQuest analysis indicated that 109 protein spots were statistically different between the two groups and, of these, 59 exhibited greater than or equal to twofold difference in spot density (Student's t test, p=0.01). Thirty-nine of these proteins were successfully identified with reliable confidence.

show abstract

Section: Discussionsupporting

confidence: 86%

Proteomic Profiling of Ovarian Cancer Plasma using Immunoaffinity Depleted Plasma and Two-Dimensional PAGE

Oliva¹,

Ayhan²,

Barker³

et al. 2007

Clin Proteom

View full text Add to dashboard Cite

show abstract

“…Our results, showing reduced expression of glutathionylated transthyretin in CRC patients in comparison to NC subjects, are thus in accordance with this theory. Moore et al (30) confirmed later the role of transthyretin, in combination with apolipoprotein A-I and CA-125, as potential biomarker of ovarian cancer (29,30).…”

Section: Discussionmentioning

confidence: 92%

“…Furthermore, increased expression of Apo A-I has been observed in liver metastases as well as, although to a lesser extent, in primary tumors of colorectal origin (35). The precise role of Apo A-I in colorectal cancer has to be determined but, taken into account the lower expression in other malignancies (29,30), we acknowledge that it is not disease specific and thus unlikely to be a selective biomarker with high specificity for colorectal cancer.…”

Section: Discussionmentioning

confidence: 98%

Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry

Helgason

Engwegen²,

Zapatka³

et al. 2010

Oncol Rep

View full text Add to dashboard Cite

Abstract. Colorectal cancer (CRC) is the second most common cause of cancer related death. Prognosis is highly dependent on stage at diagnosis making early detection mandatory. This study aimed to identify novel disease specific biomarkers of CRC, validate our previously identified biomarkers of CRC and identify serum biomarkers predicting treatment response and for monitoring. Serum of patients with metastatic CRC was collected, according to a predefined schedule, prior to start of standard first-line chemotherapy with oxaliplatin and capecitabine and serially before each 3 weekly treatment cycle and analyzed for proteomic profile by standardized SELDI-TOF MS. Serum proteomic mass spectrometry data of all subjects were processed using the tbimass R-package and proteomic profiles of CRC patients were compared with those of matched normal control subjects. Furthermore, changes in proteomic profiles during the course of chemotherapy were recorded according to treatment response. In total, 42 patients with advanced CRC were treated and mean follow-up was 13.5 months. The response rate was 50% and the median overall survival 19.5 months (95% CI: 16-23). By comparing CRC patients and healthy controls we identified 13 potential biomarkers of CRC (m/z 2.0-31.9 kDa) whereas two proteins, m/z 14060 and 28100 Da (apolipoprotein A-I), were highly significant (p<0.0001).Comparison of responding and non-responding patients identified 6 proteins potentially predicting response, where of m/z 3330 Da was significant (p=0.007). Serial analysis identified 2 proteins, m/z 2022 and 28100 Da, that changed during chemotherapy in accordance with response. We identified 13 m/z values discriminating between CRC patients and healthy controls, including the previously identified apolipoprotein A-I as a candidate biomarker for CRC and treatment monitoring.

show abstract

“…Previous studies have reported the diagnostic value of ApoA-1 and proApolipoprotein A1 (the precursor of ApoA-1) in tumor diagnosis. Decreased levels of ApoA-1 were found in a variety of cancers [18][19][20][21][22][23], but pro-ApoA-1 increased in breast cancer [24]. Marchi et al found that pro-ApoA-1 significantly increased (p<0.05) in lung cancer patients with brain metastases [25].…”

Section: Discussionmentioning

confidence: 99%

Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy

Huang¹,

Ding²,

Li³

et al. 2012

neo

View full text Add to dashboard Cite

Purpose: To find potential serum biomakers that can predict clinical outcome upon treatment in non-small cell lung cancer (NSCLC) by analyzing differential proteins in serum with different sensitivity of chemoradiotherapy (CRT).Materials and Methods: Sera were collected from 37 NSCLC patients before they were treated with concurrent cisplatinbased CRT. According to the outcome of CRT, the patients were divided into sensitive group and resistant one. The proteins in sera were separated by two-dimensional gel electrophoresis after the high abundance proteins were removed from sera. The significantly differentially expressed proteins between two groups were analyzed by liquid chromatography and tendem mass spectrometry (LC-MS/MS). Then, an additional 50 serum samples were used for ELISA analysis to validate the identified proteins that we got in the experiment.Results: Proteins in sera of each group were successfully separated on 2D gels. There were significant discrepancies in serum protein expression between NSCLC patients with different CRT sensitivity. Among eight differently expressed proteins, six proteins were successfully identified with five of which higher expressed and one lower expressed in resistant group. The increased Alpha-1-antitrypsin (α1-AT) level in resistant group comparing to sensitive one were validated by ELISA analysis (p<0.05).Conclusions: Proteomic approach may serve as a useful method in detecting the potential biomarkers for predicting the outcome of treatment in NSCLC patients. NSCLC patients with high α1-AT level in serum before CRT may have a worse treatment outcome.

show abstract

Evaluation of Apolipoprotein A1 and Posttranslationally Modified Forms of Transthyretin as Biomarkers for Ovarian Cancer Detection in an Independent Study Population

Cited by 82 publications

References 21 publications

Proteomic Profiling of Ovarian Cancer Plasma using Immunoaffinity Depleted Plasma and Two-Dimensional PAGE

Proteomic Profiling of Ovarian Cancer Plasma using Immunoaffinity Depleted Plasma and Two-Dimensional PAGE

Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry

Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy

Contact Info

Product

Resources

About